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Abstract 
Stimulation of glutamatergic tone has been causally linked to myocardial pathogenesis and 
amplified systemic blood pressure (BP). Memantine, a non-competitive N-Methyl-D-
aspartate glutamatergic receptor (NMDA-R) antagonist, has been proposed to be an active 
cardioprotective drug. However, the efficacy of memantine and subsequently the possible 
involvement of the NMDA-R in the thyroxin (T4)-induced cardiovascular complications have 
never been investigated. We examined the effect of memantine (30 mg/kg/day/I.P) on the T4 (500 
µg/kg/day/I.P)-provoked increase in mouse BP as well as cardiac hypertrophy and reformed 
reactions of the contractile myocardium both in-vivo and ex-vivo following 2 weeks of treatment. 
Memantine alone did not result in any cardiovascular pathology in mice. Instead, memantine 
significantly prevented the T4-triggered systemic hypertension. But, it did not reverse cardiac 
hypertrophy, coupled in-vivo left ventricular (LV) dysfunction or ex-vivo right ventricular (RV) 
papillary muscle contractile alterations of the T4-treated mice. Our results openly direct the 
cardiovascular safety and tolerability of memantine therapy. Yet, extra research is necessary to 
endorse these prospective advantageous outcomes. Also, we believe that this is the first study to 
inspect the possible role of NMDA-R in the T4-stimulated cardiovascular disorders and concluded 
that NMDA-R could play a key role in the T4-induced hypertension. 
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Background 
Glutamatergic neurotransmission is a remarkable excitatory pathway in the central nervous 
system, where it regulates a broad diversity of neuronal activities based on the glutamate receptor 
type.1 Generally, there are two different types of glutamate receptors, which are the ionotropic 
receptors (ligand-gated channels) and the metabotropic receptors (G protein-coupled receptors). 
The ionotropic receptors are differentiated into three subtypes in proportion to their explicit 
agonists: the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor (AMPA-R), kainite 
receptor (KA-R) and NMDA-R.1,2 
Although NMDA-R expression is well-known for the central nervous system, its 
expression has been also demonstrated in peripheral organs, including the cardiomyocytes3,4 and 
endothelial cells.5 Interestingly, NMDA-R activation has been causally associated with myocardial 
pathogenesis, such as heart failure,6,7 ventricular arrhythmias8 and atrial fibrillation,9 in addition 
to systemic hypertension.10 These cardiac pathologies evoked by the activation of NMDA-R were 
attributed to increased oxidative stress, calcium overload, cardiomyocyte apoptosis,1 myocardial 
fibrosis8 and stimulation of myocyte mitochondrial matrix metalloproteinase.11  
Similar to the NMDA-R activation, increased thyroid hormones (TH), a well-documented 
modulator of cardiovascular function, can trigger heart failure,12,13 ventricular arrhythmias,14 atrial 
fibrillation,15 as well as systemic hypertension.16-18 Additionally, some analogous cardiac 
mechanisms were reported in the TH-induced cardiovascular pathology, counting the oxidative 
stress,19, 20 cardiomyocyte apoptosis21 and matrix metalloproteinase.22 
Depending on these parallel outcomes, we hypothesized that NMDA-R may be involved 
in the TH-aggravated cardiac remodeling and hemodynamic changes. Thus, in the current study, 
this hypothesis was examined by exploring the effect of memantine, a non-competitive NMDA-R 
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antagonist, on the T4-driven increase in BP as well as cardiac hypertrophy and reformed reactions 
of the contractile myocardium both in-vivo and ex-vivo in mice.  
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Methods 
Animals 
 Adult (9-12 months old) FVB/N male mice were purchased from the Jackson Laboratory 
(Bar Harbor, ME) and kept at the Research Animal Facility of The Ohio State University for the 
whole duration of the experimental procedures. The experimental procedures and protocols used 
in this study were approved by the Animal Care and Use Committee of the Ohio State University, 
conforming to the Guide for the Care and Use of Laboratory Animals published by the United 
States National Institutes of Health (National Institutes of Health publication No. 85–23, revised 
1996). 
 
Thyroxin (T4) and Memantine HCL Treatments 
T4, sodium-L-thyroxin, from Sigma-Aldrich (St. Louis, MO) was prepared as previously 
described23 and injected intraperitoneally at a dose of 500 mg/kg/day for 2 weeks as we reported 
before.24-26 Memantine HCL from Sigma-Aldrich (St. Louis, MO) was dissolved in normal saline 
and administered at a dose of 30 mg/kg/day by intraperitoneal injection prior to T4. Memantine 
dose was chosen based on a previous study showed that 30 mg/kg/day in mice constructs the 1 μM 
therapeutic steady-state plasma level as indicated by numerous preclinical and clinical studies.27 
Mice were divided into 4 groups based on treatment; vehicle (control group) (n = 16), memantine 
only (n =14), T4 only (n = 17) and memantine + T4 (n = 15). At the end of the treatment period, 
mice underwent BP measurements, echocardiography and electrocardiogram (ECG). Thereafter, 
mice were sacrificed, and hearts were removed and processed for further experiments. 
 
Blood pressure (BP) measurements 
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BP was measured noninvasively in conscious untrained mice by the tail cuff method 
using a six-Channel CODA High Throughput Acquisition system (Kent Scientific Corporation, 
Torrington, CT, USA) as described before.25 Each experimental session consisted of 10 
acclimatization cycles followed by 10 BP measurements cycles. Only the accepted cycles as 
identified by the BP measurement software are included in the data analysis. The average of all 
accepted cycles from one session was used for systolic BP (SBP), diastolic BP (DBP), and mean 
arterial pressure (MAP) in each mouse. 
 
Echocardiography 
 
The in-vivo LV dimension and contractile function in mice were evaluated by using a high-
frequency ultrasound imaging system (VEVO 2100, Visual Sonics, Toronto, ON, Canada) as 
described before.23-26 Mice were anesthetized with isoflurane at a concentration of 3 % and 
thereafter maintained at 1.5 % isoflurane via nasal prongs during the whole procedure. The 
measurements were taken from the parasternal short-axis view in M-mode to view the LV 
movement during systole and diastole corresponding to the electrocardiogram. All data and 
imaging were analyzed by the Visual Sonics Cardiac Measurements Package. 
 
Electrocardiogram (ECG) 
ECG parameters including heart rate (HR), PR, QRS, and QT intervals were recorded 
noninvasively in fully conscious and unrestrained mice using the ECGenie system (Mouse 
Specifics, Inc., MA). Mice were placed onto the recording platform for sufficient time (about 30 
minutes) to acclimate and trigger recordings when their paws are in contact with the recording 
electrodes. All data were then analyzed by e-MOUSE, a Physiological Data Analysis and Database 
Portal, as we previously reported.24,26 
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Heart weight (HW), cardiac muscle preparation and experimental setup 
 
First, mice were weighed, and five minutes after I.P heparin injection mice were euthanized 
by cervical dislocation. After bilateral thoracotomy, hearts were rapidly excised and placed in 
Krebs–Henseleit buffer containing (in mmol/L): 120 NaCl, 5 KCl, 2 MgSO4, 1.2 NaH2PO4, 20 
NaHCO3, 0.25 Ca
2+, and 10 glucose, equilibrated with 95% O2- 5% CO2, resulting in a pH of 7.4. 
Additionally, 20 mmol/L 2,3-butanedione monoxime (BDM) was added to the dissection buffer 
to prevent cutting injury.24-26 Extra non-cardiac tissues, such as fat and pieces of lung, were 
carefully removed. After hearts were blotted gently on Kim wipes they rapidly transferred to a 
small weigh dish that contained clean oxygenated Krebs–Henseleit/BDM buffer that was tarred to 
zero on an electronic analytical balance to get the exact wet HW. HW/body weight (BW) ratios 
were then calculated and expressed as mg/g. Hearts were then carefully opened, repeatedly 
perfused with the same oxygenated Krebs–Henseleit/BDM buffer, and blood was thoroughly 
washed out. From the RV, uniform linear papillary muscles were carefully dissected. The 
dimensions of muscles were measured using a calibration reticule in the ocular of the dissection 
microscope (40x, resolution ~10 µm). The cross-sectional areas were calculated assuming 
ellipsoid cross-sectional shapes. There was no significant difference between average dimensions 
(width x thickness x length) of the control (0.25 ± 0.02 x 0.16 ± 0.01 x 1.02 ± 0.10 mm), memantine 
(0.25 ± 0.02 x 0.16 ± 0.01 x 0.80 ± 0.08 mm), T4 (0.30 ± 0.02 x 0.20 ± 0.02 x 0.88 ± 0.08 mm) 
and memantine +T4 (0.29 ± 0.02 x 0.19 ± 0.01 x 0.88 ± 0.06 mm). P values are 0.1219, 0.1097, 
and 0.3265, respectively. 
With the use of the dissection microscope, muscles were mounted between basket-shaped 
extension of a force transducer (KG7, Scientific Instruments, Heidelberg, Germany) and a hook 
(valve end) connected to a micromanipulator as previously mentioned.24-26 Muscles were 
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superfused with the same buffer at 37.5ᴼC as above (with the exception that BDM was omitted) 
and stimulated at 4 Hz. Extracellular Ca2+ concentration was raised to 2 mmol/L and muscles were 
allowed to stabilize for at least 30 minutes before the experimental protocol was initiated. The 4 
Hz baseline was selected rather than a more physiological 12 Hz, as in our previous reports.24-26 
However, to study more physiological frequencies, 12 Hz contractions were also assessed, but only 
for brief periods. Generally, muscles were stretched to an optimal length where a small increase in 
length resulted in nearly equal increases in resting tension and active developed tension. This 
length was selected to be comparable to the maximally attained length in-vivo at the end of 
diastole.28 
To obtain a broad scope of quantitative data to dissect contractile function and dysfunction, 
two of the three main mechanisms utilized in-vivo to physiologically modify force of contraction, 
frequency-dependent activation, and β-adrenergic stimulation were assessed in mouse papillary 
muscles under near physiological conditions as previously described.24-26 This is because the third 
mechanism, which is the length-dependent activation (Frank-Starling mechanism) is well-
sustained in the hearts of these T4-treated mice.25 We assessed the effect of increasing stimulation 
frequencies between 4 and 14 Hz, spanning the entire in-vivo range of the mouse. At each 
frequency, forces were allowed to reach steady state before data were recorded. The effects of β-
adrenergic stimulation were also assessed by a concentration–response curve with isoproterenol 
(10-9–10-6 mol/L) at a baseline stimulation frequency of 4 Hz. 
In all experiments performed peak isometric developed force (Fdev) was determined and 
normalized to the cross-sectional area of the muscle. Additionally, as a force-independent 
parameter of force decay kinetics, time to peak force (TTP), and time from peak force to 50% 
relaxation (RT50) were determined. Muscles with an initial Fdev or a Fdev after re-stabilization 
10 
 
following frequency-dependent activation < 5 mN/mm2 were excluded from the analysis of all 
experimental parameters. Additionally, muscles that displayed arrhythmia early at the initial 
isoproterenol concentrations were excluded from the final isoproterenol-Fdev data analysis. 
Furthermore, muscles that exhibited arrhythmia after the FFR and before starting the isoproterenol 
experiments were not included either in the arrhythmia or in the final isoproterenol-Fdev data 
analysis (1 muscle from the control group and 1 from the T4 group). 
 
Data analysis and statistics 
Generally, a two-tailed value of P ≤ 0.05 was considered statistically significant. Data are 
presented as mean ± SEM and were analyzed by either ordinary one-way analysis of variance 
(ANOVA) or repeated measures ANOVA followed by Tukey-Kramer’s post-hoc multiple 
comparison test. Ordinary one-way ANOVA assumes that the data are sampled from populations 
that follow Gaussian distributions. This assumption was tested using Kolmogorov and Smirnov 
test, which showed that all data sampled passed normality test. Also, it assumes that the data are 
sampled from populations with identical SDs and this assumption was tested using Bartlett test. 
The cases, in which Bartlett test suggested significant differences among the SDs of the groups 
Kruskal-Wallis test (nonparametric ANOVA) was applied followed by Dunn’s post-hoc multiple 
comparison test. On the other hand, ordinary repeated measures ANOVA assumes effective 
matching amongst means. If the matching appears not to be effective, Friedman test 
(nonparametric repeated measures ANOVA) was applied followed by Dunn’s post-hoc multiple 
comparison test.   
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Results 
 First, we did not observe a significant difference in the SBP (113.90 ± 3.96 mmHg), DBP 
(85.84 ± 4.30 mmHg) and MAP (94.83 ± 4.14 mmHg) of the mice treated only with memantine 
compared to the control (118.40 ± 2.23 mmHg), (94.24 ± 2.23 mmHg) and (101.91 ± 2.20 mmHg), 
respectively (Figure 1A-C). Conversely, the T4 treatment as expected16-18,24-26 significantly 
increased the SBP (141.77 ± 3.05 mmHg; p<0.001), DBP (112.11 ± 3.06; mmHg p<0.001) and 
MAP (121.72 ± 3.05 mmHg; p<0.001) compared to both the control and the memantine only-
treated mice (Figure 1A-C). Notably, concomitant administration of memantine with T4 
significantly reduced the remarkably amplified SBP, DBP and MAP following T4 treatment to a 
level that was not significant compared to both the control and the memantine only-treated mice 
(119.79 ± 3.17 mmHg; p<0.001), (87.77 ± 3.27 mmHg; p<0.001) and (98.15 ± 3.20 mmHg; 
p<0.001), respectively (Figure 1A-C).     
Echocardiography analysis illustrated that memantine treatment could not cause a 
significant change in the LV ejection fraction (EF) (66.23 ± 0.68 %) (Figure 2A) or the fractional 
shortening (FS) (36.07 ± 0.50 %) (Figure 2B) compared to those of the control (EF: 67.59 ± 0.87 
% and FS: 37.23 ± 0.64 %). However, in agreement with our former outcomes24-26 as well as with 
others’ data,12,13 the T4 treatment led to LV systolic dysfunction as revealed by significantly 
decreased EF (58.79 ± 1.40 %) (Figure 2A) and FS (30.99 ± 0.96 %) (Figure 2B) compared to 
those of both the control (EF: p < 0.001 and FS: p < 0.001) and the memantine only-treated mice 
(EF: p < 0.01 and FS: p < 0.01). Also, concomitant administration of memantine with T4 could 
not inhibit the T4-prompted reduction in either the EF or the FS and they were still significantly 
lower than those of the control (EF: 60.63 ± 1.32 %; p < 0.01 and FS: 32.31 ± 0.93 %; p < 0.01) 
(Figure 2A, B). Furthermore, echocardiographic assessment demonstrated that mice with 
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memantine alone had no significant changes in the LV mass (108.69 ± 4.01 mg) (Figure 2C) or 
the LV mass/BW ratio (3.75 ± 0.12 mg/g) (Figure 2D) compared to those of the control (LV mass: 
106.24 ± 3.40 mg and LV mass/BW: 3.63 ± 0.09 mg/g). Nevertheless, the T4 treatment as we 
reported before24-26 resulted in a marked increase in the LV mass (157.37 ± 5.82 mg; p < 0.001) 
(Figure 2C) and LV mass/BW ratio (5.09 ± 0.14mg/g; p < 0.001) (Figure 2D) compared to those 
of both the control and the memantine only-treated mice. Memantine along with T4 treatment 
could not significantly diminish such T4-accelerated increases in LV mass or LV mass/BW ratio 
and they were still significantly higher than those of the control and the memantine only-treaded 
mice (148.09 ± 5.15 mg; p < 0.001 and 5.18 ± 0.17 mg/g; p < 0.001, respectively) (Figure 2C, D). 
On the other hand, the ECG analysis showed no significant difference in any of the parameters 
that were measured (HR, PR, QRS and QT) among all groups, including the T4-treated mice as 
we formerly defined24, 26 (Table 1). 
Evaluation of the BW using the Kruskal-Wallis test showed a P value of 0.0408, which is 
considered significant. However, the Dunn's Multiple Comparisons test demonstrated a non-
significant difference amongst the groups: control (29.53 ± 0.30 g), memantine (28.92 ± 0.39 g), 
T4 (30.88 ± 0.59) and memantine + T4 (28.74 ± 0.63 g). Yet, there was a quite non-significant 
difference in the BW of the memantine (P = 0.0815) and the memantine + T4 (P = 0.0968) 
compared to the T4-treated mice (Figure 3A). Besides, there was no significant difference in the 
HW (136.69 ± 2.42 mg) or the HW/BW ratio (4.73 ± 0.05 mg/g) of the mice treated with 
memantine alone compared to those of the control mice (HW: 139.13 ± 2.10 mg and HW/BW: 
4.71 ± 0.06 mg/g) (Figure 3B). Alternatively, T4 treatment significantly increased both HW 
(186.83 ± 3.71 mg: p < 0.001) and HW/BW ratio (6.06 ± 0.09: p < 0.001) compared to both the 
control and the memantine only-treated mice (Figure 3C), which confirms the development of 
13 
 
cardiac hypertrophy in harmony with our previous reports.24-26 Memantine administration along 
with T4 treatment did not significantly decrease the T4-evoked increase in HW or HW/BW ratio 
and were still notably higher than those of the control and memantine-only treated mice (HW: 
183.34 ± 5.30 mg; p < 0.001 and HW/BW: 6.40 ± 0.20 mg/g; p < 0.001) (Figure 3B, C). 
Finally, under proximate physiological temperature and at a preload leading to sarcomere 
length around the in-vivo end-diastolic values of 2.2 μm,28 the ex-vivo experiments exemplified 
that there is no significant difference in the Fdev of the RV papillary muscles amongst the groups 
(p = 0.4684) at a stimulation frequency of 4 Hz, including the T4 group resembling our earlier 
records (24-26): control: 26.0 ± 3.7 mN/mm2, memantine: 22.6 ± 4.6 mN/mm2,T4: 19.6 ± 1.9 
mN/mm2 and memantine + T4: 17.2 ± 3.0 mN/mm2) (Figure 4A). Moreover, muscles from the 
control and the memantine only-treated mice exhibited similar contractile profile as indicated by 
comparable TTP (47.1 ± 1.2 ms vs. 46.3 ± 1.7 ms) (Figure 4B) and RT50 (24.6 ± 1.7 ms vs. 31.1 
± 1.8 ms), respectively (Figure 4C). Inversely, the muscles from the T4-treated mice demonstrated 
faster contraction and relaxation as we explained before24-26 by significantly declining the TTP 
(39.1 ± 0.7 ms) and the RT50 (18.9 ± 0.8 ms) compared to those of the control (TTP; p < 0.01 and 
RT50; p < 0.05) and the memantine only group (TTP; p < 0.05 and RT50: p < 0.001) (Figure 4B, 
C). Additionally, concomitant administration of memantine with T4 was not able to significantly 
change the T4-induced decrease in the TTP (38.4 ± 1.1 ms) or the RT50 (19.3 ± 0.8 ms). The TTP 
of memantine +T4 group was still significantly lower than those of the control (p < 0.001) and the 
memantine only group (p < 0.01), However, the RT50 of the memantine + T4 group was only 
significant compared to the memantine only (p< 0.001), but not the control group (p = 0.1558) 
(Figure 4B, C). 
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Fdev was also assessed within the murine in-vivo physiological range (8–12 Hz) along with 
the baseline stimulation frequency of 4 Hz. Muscles from the T4-treated mice exhibited a 
significantly negative response to the increasing frequency at 10 Hz (versus memantine; p < 0.05), 
12 Hz (versus control; p < 0.05) and 14 Hz (versus control; p < 0.05) as indicated by ordinary one-
way ANOVA and there was no significant differences amongst the rest of the groups (Figure 3A). 
On the other hand, Friedman test of repeated measures ANOVA displayed a substantial influence 
for both the group (P<0.001) and frequency (P<0.001) variations on the Fdev. But, there was no 
considerable interaction between the 2 variants. Notably, the force frequency response in this study 
is somewhat different from our previous reports,24-26 where the control mice (7 - 9 months) 
typically show a considerable positive response compared to the negative response that we 
demonstrated here (9 - 12 months). The most likely explanation is that the mouse’s age seems to 
be a key factor. We have illustrated that isolated papillary muscles from the older wild-type FVB/N 
mice RV (12 - 14 months) exhibited a slightly negative force frequency response,29 in addition to 
a similar response that we have recently discovered in another group of mice (9 - 10 months) (data 
not shown). The mice used in these studies are retired breeders and the exact age is not guaranteed. 
Furthermore, the impact of the β-adrenergic stimulation was assessed by a concentration–
response curve with isoproterenol (10−9–10−6 mol/L) at a baseline stimulation frequency of 4 Hz. 
Under maximal β-adrenergic stimulation (1 μmol/L isoproterenol), there was no significant 
difference between muscle response of the control and the memantine only-treated mice. 
Nonetheless, Kruskal-Wallis test confirmed our preceding facts24-26 and revealed that muscles from 
the T4-treated mice demonstrated a strikingly declined response versus those of the control (P < 
0.01), but not the memantine only (P = 0.0769) group (Figure 3B). Memantine treatment could 
not prevent this dampened isoproterenol response in the muscles of the T4-treated mice and it 
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continue to be considerably reduced compared to the muscles of control (p < 0.01) and memantine 
only-treated mice (P <0.05) (Figure 3B). Besides, repeated measures ANOVA presented a notable 
effect for the group (P<0.001) and the isoproterenol concentration (P<0.001) variations on the 
Fdev, along with a substantial interaction between the 2 variants (P < 0.001). Finally, at maximal 
β-adrenergic stimulation, muscles of the T4 as well as the memantine + T4 groups exhibited 
arrhythmia in undoubtedly higher number of muscles (8/13 and 8/11, respectively) compared to 
those of the control (3/13) and the memantine alone (2/12) (Figure 3C). 
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Discussion 
Thyroid hormones affect the glutamatergic neurotransmission pathway in the central 
nervous system, where they have been anticipated as a key modulator of NMDA-R subunit 
expression in the hippocampus.30 In addition, Losi et al. reported that thyroid hormones 
nongenomically regulate the activity of the NMDA-R and repressed the neuronal death driven by 
glutamate.31 Moreover, it has been shown that hypothyroidism could protect from cerebral 
ischemia due to subsequent decrease in glutamate release.32 However, the relation between this 
glutamatergic pathway and thyroid hormone in the peripheral tissue, in particular, the 
cardiovascular system, has never been exposed. Previous studies reported that NMDA-Rs are 
widely expressed in the hearts of human and rodent.33,34 The NMDA-R expression has been also 
detected in the vasculature, including the aorta and pulmonary artery.34 In the vein of thyroid 
hormone, NMDA-R activation has been linked to some kind of circulatory diseases, such as heart 
failure, cardiac arrhythmias and hypertension.6-10 Therefore, it is rational to assume that the 
NMDA-R could be a prospective intervention target for the T4-induced cardiovascular changes 
and we believe that this is the first study to examine this hypothesis. 
Memantine is a non-competitive NMDA-R antagonist35 characterized by a fast-
binding/dissociating activity, which allows for a fast course of action and less effect on physiologic 
functions compared to the other NMDA-R antagonists.36,37 Hence, memantine has been stated to 
offer much promise in the treatment of neurodegenerative disorder,38 and is presently used in 
moderate to severe Alzheimer’s disease (AD) patient therapy in the US and Europe.37,39 
Memantine has been also shown to be a non-competitive antagonist of both the serotonin (5-HT3) 
receptors40 and the nicotinic cholinergic receptors,41 as well as a dopaminergic receptor agonist.42 
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Yet, when used in combination therapy, for example, its 5HT-3 antagonism could prevent the 
acetyl cholinesterase inhibitor gastrointestinal side effects.37 
Memantine is a well-tolerated drug,37 so far little is known about its cardiovascular 
effects.43 Clinical trials have shown that hypertension is one of the memantine side effects occurred 
in > 2% of the patients at a larger rate compared to the placebo-treated patients, but, it did not 
reach significance.37 In the current study, we showed that memantine has no significant effect on 
the mouse BP. In agreement with our results, memantine at a similar dose (32 mg/kg) did not 
significantly affect the rat BP as well44 and similarly the AP-5, an NMDA-R antagonist resulted 
in a very slight change in the BP of the sham rat.7  
In addition, a number of compromised cardiac upshots have been reported following 
memantine therapy. For instance, an increase in the deadly and non-deadly myocardial infarction 
in the users of memantine has been reported in a comparison of the users and non-users of 
memantine in two large population databases. Though, this might be partly because of the sicker 
individual selection for memantine treatment.43,45 Also, concomitant administration of memantine 
with donepezil in AD patient was displayed to increase the ECG PR interval.46 Besides, memantine 
has been conveyed to exacerbate the ECG corrected QT interval in the AD patients.47,48 However, 
these patients have been diagnosed with severe heart diseases, in addition to old age and diabetes, 
which are known risk factors for the prolonged corrected QT interval.47 Conversely, prolonged 
corrected QT interval was not recorded in the French PharmacoVigilance Database report 
regarding the patients receiving memantine therapy, and a small number of adverse cardiovascular 
effects, above all, cardiac bradycardia was documented.49 Compatibly, the (+)-MK801, a 
noncompetitive NMDA receptor antagonist, was demonstrated to prompt bradycardia and positive 
inotropy in isolated rat cardiac tissues (Right atria, left atria and right ventricular strips).3 Overall, 
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it has been suggested that memantine cardiovascular properties appear to be complicated, pretty 
indistinct and require further experimental and clinical studies.49 Here, we showed that memantine 
could not induce any considerable alteration in the cardiac structure and function as evidenced by 
the typical HW, in-vivo echocardiographic LV structure/function, ECG parameters (HR, PR, QT, 
and QRS) and ex-vivo RV contractile performance following memantine treatment in comparison 
to the control mice. Merely, memantine prolonged the relaxation time (RT50) of the contractile 
RV muscles, however, it did not reach significance (P = 0.1994; Kruskal-Wallis test). Theses 
valuable endings have been observed in the mice treated not only with the memantine alone, but 
also in combination with the T4 treatment, which resulted in numerous cardiac variations that were 
sufficient to increase the risk for cardiac mortality, even so, it did not befall. These data openly 
direct the cardiovascular safety and tolerability of memantine therapy. Yet, extra research is 
necessary to endorse these prospective advantageous outcomes. 
On the other side, memantine has shown some cardiac therapeutic effects. D’Amico et al. 
conveyed that NMDA/non-NMDA inotropic excitatory amino acid antagonists, including 
memantine, are effective in preventing the reperfusion-induced, but not the ischemia-induced 
cardiac arrhythmia and mortality in rats.50 Additionally, it has been reported that memantine could 
prevent the reduction in the rat LV cardiomyocyte nuclear size induced by cold stress, which has 
been suggested to either initiate or increase the rodent cardiovascular dysfunction,51,52 concluding 
that memantine might be a promising cardioprotective medication.51 Actually, NMDA-R has been 
shown to play a key role in the induction of several heart failure/decreased cardiac contractility 
related pathways, such as the sympathoexcitation,6,7 oxidative stress, calcium overload, 
cardiomyocyte apoptosis,1,53 myocardial fibrosis8 and stimulation of myocyte mitochondrial 
matrix metalloproteinase.11 Even though T4-induced cardiac remodeling has been referred to 
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similar mechanisms, including the sympathetic nervous system,54 oxidative stress,19,20 
cardiomyocyte apoptosis21 and matrix metalloproteinase,22 memantine could not inhibit any of the 
T4-induced cardiac pathological manifestations in the current study. Furthermore, NMDA-R-
associated reduction in the cardiomyocyte contractility has been reported to be linked to 
prolongation in the TTP and RT11,53 in contrast to the T4-evoked reduction in both parameters in 
the RV muscles of this model.  
Prominently, molecular,7 immunocytochemical55 and biochemical56 records have 
displayed that the NMDA-R expression could be adapted by alterations in the systemic BP. 
NMDA-R has been reported to markedly contribute to the hypertension prompted by raised 
sympathoexcitation associated with the left coronary ligation-induced heart failure in rats,7 
angiotensin II57 and carotid clamping in the rostral ventrolateral medulla of anesthetized rats.58 In 
consistency with these outcomes, memantine, an NMDA-R blocker, significantly reduced the T4-
induced hypertension in our model. Interestingly, a recent study revealed that the glutamatergic 
neurotransmission in the rostral ventrolateral medulla of conscious rats depends on the nitric oxide 
(NO)-NMDA-R pathway excitatory effects to control the systemic BP.10 Indeed, we25 and others18 
have shown that the NO synthase (NOS) pathway is a key player in the T4-evoked hypertension. 
Generally, the activation of the NOS has been reported in the hyperdynamic circulation following 
hyperthyroidism. While endothelial NOS (eNOS) and inducible NOS (iNOS) could have a 
homeostatic role, neuronal NOS (nNOS) was projected as the crucial factor in the 
hyperthyroidism-induced hypertension in rats.16-18 Notably, the nNOS activation with the 
subsequent NO production has been reported as a strategic NMDA-R signaling transducer59 and 
has been involved in the regulation of BP and neurogenic hypertension as well.60 Based on these 
findings, we strongly believe that the inhibitory effects of memantine on the NO-NMDA-R 
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excitatory pathway could potentially be the main mechanism resulted in the significant prevention 
of the T4-induced hypertension in this study. However, future investigation for further 
confirmation is warranted.  
 
Conclusions:  
Overall, our results openly direct the cardiovascular safety and tolerability of memantine 
therapy. Yet, extra research is necessary to endorse these prospective advantageous outcomes. 
Also, we believe that this is the first study to inspect the possible role of NMDA-R in the T4-
stimulated circulatory disorders. Finally, our data show for the first time that NMDA-R could play 
a key role in the T4-induced hypertension, but not cardiac remodeling. 
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Figure Legends 
Figure 1. Blood pressure (BP) measurements of mice. (A) SBP, systolic blood pressure; (B) 
DPB, diastolic blood pressure; (C) MAP, mean arterial pressure. Control; n = 16, Memantine; n = 
14, Thyroxin (T4); n = 17, Memantine + T4; n = 15. #, indicates a significant change compared to 
the T4 group; +, indicates a significant change compared to both the Control and the Memantine 
groups. One-way ANOVA followed by Tukey-Kramer’s post-hoc multiple comparison test. 
Figure 2. Echocardiography Analysis of Mouse Hearts. (A) Ejection fraction (EF), (B) 
Fractional shortening (FS), (C) left ventricle (LV) mass and (D) LV mass/body weight (BW) ratio. 
Control; n = 16, Memantine; n = 14, Thyroxin (T4); n = 17, Memantine + T4; n = 15. *, indicates 
a significant change compared to the control; +, indicates a significant change compared to both 
the Control and the Memantine groups. EF and FS; Kruskal Wallis test followed by Dunn’s post-
hoc multiple comparison test. LV mass and LV mass/BW ratio; one-way ANOVA followed by 
Tukey-Kramer’s post-hoc multiple comparison test. 
Figure 3. Morphological data. (A) Body weight (BW), (B) heart weight (HW) and (C) HW/BW. 
Control; n = 15, Memantine; n = 14, Thyroxin (T4); n = 17, Memantine + T4; n = 14. +, indicates 
a significant change compared to both the Control and the Memantine groups. Kruskal Wallis test 
followed by Dunn’s post-hoc multiple comparison test. 
Figure 4. Contractile profile of isolated right-ventricular papillary muscles. (A) Mean active 
isometric developed force (Fdev), (B) corresponding time to peak (TTP), and (C) 50% relaxation 
time (RT50) at 4 Hz stimulation frequency and 2 mmol/L Ca
2+. Control; n = 14, Memantine; n = 
12, Thyroxin (T4); n = 14, Memantine + T4; n = 11. !, indicates a significant change compared to 
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the Memantine group. +, indicates a significant change compared to both the Control and the 
Memantine groups. Kruskal Wallis test followed by Dunn’s post-hoc multiple comparison test. 
Figure 5. (A) Force-frequency relationship of isolated right ventricular papillary muscles. 
Peak isometric developed force (Fdev) values are expressed as a fraction of its corresponding Fdev 
at the basal frequency of 4 Hz and presented as mean ± SEM. Control; n = 14, Memantine; n = 12, 
Thyroxin (T4); n = 14, Memantine + T4; n = 11. One-way ANOVA followed by Tukey-Kramer’s 
post-hoc multiple comparison test. (B) β–adrenergic stimulation of isolated right ventricular 
papillary muscles. Fdev values following β–adrenergic stimulation are expressed as ΔFdev, 
which is the change in the Fdev at (10-6 mol/l) isoproterenol in regard to its corresponding Fdev at 
the basal condition. Control; n = 13, Memantine; n = 11, Thyroxin (T4); n = 13, Memantine + T4; 
n = 8. Kruskal Wallis test followed by Dunn’s post-hoc multiple comparison test at all 
isoproterenol concentrations, except the 10-8 M (One-way ANOVA followed by Tukey-Kramer’s 
post-hoc multiple comparison test). (C) Arrhythmic activity following β-adrenergic 
stimulation. #, indicates a significant change compared to the T4 group. ϖ, indicates a significant 
change compared to both the T4 and the (Memantine + T4) groups. τ, indicates a significant change 
compared to the (Memantine + T4) group.   , indicates a significant change compared to both the 
group and frequency variation (Friedman nonparametric repeated measures ANOVA followed by 
Dunn’s post-hoc multiple comparison test) or the group and the isoproterenol concentration 
variations (repeated measures ANOVA followed by Tukey-Kramer’s post-hoc multiple 
comparison test). Error bars of the 2 upper groups; Control (   ) and Memantine (I). Significance 
marks are directly above the error bar of the statistically significant group.  
 
 
